Mira Pharmaceuticals Inc
MIRA1.630USD
+0.020+1.24%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
64.40MMarket Cap
LossP/E TTM
More Details of Mira Pharmaceuticals Inc Company
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Mira Pharmaceuticals Inc Info
Ticker SymbolMIRA
Company nameMIRA Pharmaceuticals Inc
IPO dateAug 03, 2023
CEOAminov (Erez)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 03
Address1200 Brickell Avenue
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33131
Phone18133695150
Websitehttps://mirapharmaceuticals.com/
Ticker SymbolMIRA
IPO dateAug 03, 2023
CEOAminov (Erez)
Company Executives of Mira Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.53M
+317.92%
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
64.04K
+53.71%
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
3.53M
+317.92%
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
64.04K
+53.71%
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Aminov (Erez)
8.43%
Bay Shore Trust
6.07%
McNulty (Brian Patrick)
1.88%
Candace Shira Associates, LLC
0.86%
The Vanguard Group, Inc.
0.49%
Other
82.28%
Shareholders
Shareholders
Proportion
Aminov (Erez)
8.43%
Bay Shore Trust
6.07%
McNulty (Brian Patrick)
1.88%
Candace Shira Associates, LLC
0.86%
The Vanguard Group, Inc.
0.49%
Other
82.28%
Shareholder Types
Shareholders
Proportion
Individual Investor
10.59%
Corporation
6.07%
Investment Advisor
2.11%
Investment Advisor/Hedge Fund
0.65%
Hedge Fund
0.22%
Bank and Trust
0.12%
Venture Capital
0.09%
Research Firm
0.06%
Other
80.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
1.09M
5.69%
-477.28K
2025Q2
47
4.32M
25.51%
-1.16M
2025Q1
46
4.32M
25.55%
-1.05M
2024Q4
43
5.04M
30.44%
+126.78K
2024Q3
32
4.85M
30.17%
+141.67K
2024Q2
31
5.02M
33.99%
+17.84K
2024Q1
26
4.94M
33.45%
+544.51K
2023Q4
22
5.81M
39.33%
+1.52M
2023Q3
15
5.82M
39.43%
+2.33M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Aminov (Erez)
844.70K
4.43%
+62.50K
+7.99%
Aug 29, 2025
Bay Shore Trust
2.54M
13.32%
--
--
Jul 21, 2025
McNulty (Brian Patrick)
789.05K
4.14%
--
--
Jul 21, 2025
Candace Shira Associates, LLC
359.40K
1.88%
-4.00K
-1.10%
Jun 30, 2025
The Vanguard Group, Inc.
117.82K
0.62%
--
--
Jun 30, 2025
Geode Capital Management, L.L.C.
135.29K
0.71%
-123.00
-0.09%
Jun 30, 2025
Suncoast Equity Management, LLC.
103.29K
0.54%
--
--
Jun 30, 2025
Shekhat (Denil Nanji)
41.67K
0.22%
+41.67K
--
Jul 21, 2025
First American Bank
20.00K
0.1%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Mira Pharmaceuticals Inc?
The top five shareholders of Mira Pharmaceuticals Inc are:
Aminov (Erez) holds 844.70K shares, accounting for 4.43% of the total shares.
Bay Shore Trust holds 2.54M shares, accounting for 13.32% of the total shares.
McNulty (Brian Patrick) holds 789.05K shares, accounting for 4.14% of the total shares.
Candace Shira Associates, LLC holds 359.40K shares, accounting for 1.88% of the total shares.
The Vanguard Group, Inc. holds 117.82K shares, accounting for 0.62% of the total shares.
Aminov (Erez) holds 844.70K shares, accounting for 4.43% of the total shares.
Bay Shore Trust holds 2.54M shares, accounting for 13.32% of the total shares.
McNulty (Brian Patrick) holds 789.05K shares, accounting for 4.14% of the total shares.
Candace Shira Associates, LLC holds 359.40K shares, accounting for 1.88% of the total shares.
The Vanguard Group, Inc. holds 117.82K shares, accounting for 0.62% of the total shares.
What are the top three shareholder types of Mira Pharmaceuticals Inc?
The top three shareholder types of Mira Pharmaceuticals Inc are:
Aminov (Erez)
Bay Shore Trust
McNulty (Brian Patrick)
Aminov (Erez)
Bay Shore Trust
McNulty (Brian Patrick)
How many institutions hold shares of Mira Pharmaceuticals Inc (MIRA)?
As of 2025Q3, 44 institutions hold shares of Mira Pharmaceuticals Inc, with a combined market value of approximately 1.09M, accounting for 5.69% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -19.82%.
What is the biggest source of revenue for Mira Pharmaceuticals Inc?
In --, the -- business generated the highest revenue for Mira Pharmaceuticals Inc, amounting to -- and accounting for --% of total revenue.
